Radius Health | Gurnet Point Capital

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health*.

Investment Date

2022

Status

Current

Website

https://radiuspharm.com

Related News

September 20, 2023

Radius Health Announces Expansion of its Bone Health Business Through the Exclusive Licensing of U.S. Rights to BINOSTO® for Osteoporosis

Read

August 14, 2023

Radius Announces Royalty Purchase Agreement With DRI Healthcare to Sell a Portion of Its Royalty and Commercial Milestone Interest in elacestrant for up to $140 Million

Read

Theramex enters into an exclusive licensing agreement with Radius Health Inc, to commercialise ELADYNOS®

Read

January 30, 2023

Radius Licensee Receives FDA Approval for ORSERDU™ (elacestrant)

Read

Fund II investments referenced herein have been completed by GPC through a warehouse facility provided by B-Flexion and are expected to be transferred to Fund II following its first closing. References to Fund II's investment activity to date are references to investments made by the warehouse facility.